Stanoxyl Depot 50 mg is a water-based stanozolol injectable manufactured by Kalpa Pharmaceuticals and dosed at 50 mg/mL in a 10 mL vial.
Stanoxyl Depot 50 mg is an injectable anabolic-androgenic steroid containing stanozolol, a synthetic derivative of dihydrotestosterone (DHT). Unlike most injectable steroids, stanozolol is presented as a water-based suspension rather than an oil solution. This formulation is historically associated with the brand name Winstrol Depot.
Stanozolol is not currently marketed as an FDA-approved human pharmaceutical product in the United States. The original Winstrol brand was discontinued by its manufacturer. In non-medical bodybuilding settings, stanozolol is commonly referenced during cutting phases for its hardening effects and its lack of aromatization.
Stanozolol promotes muscle protein synthesis through androgen receptor activation. When used at supraphysiologic levels for physique or performance enhancement, the potential for adverse effects also increases and such use falls outside approved medical indications.
Stanoxyl Depot 50 mg uses a water-based formulation rather than an oil carrier. This water-based presentation is characteristic of stanozolol injectable preparations and distinguishes them from oil-based anabolic injectables.
Stanozolol is a DHT-derived anabolic steroid designed for non-aromatizing properties. Its water-based injectable form and lack of estrogen conversion distinguish it from testosterone and other aromatizable compounds.
Stanozolol is a derivative of dihydrotestosterone, which lacks the ability to be aromatized to estrogen. This structural characteristic is why stanozolol does not cause water retention or gynecomastia through the aromatization pathway. It also cannot be reduced by 5-alpha-reductase since it is already a DHT derivative.
Stanozolol injectable is presented as a water-based suspension. This means the compound is not dissolved in oil but suspended in water, which affects its absorption characteristics and injection-site considerations. The water-based formulation is characteristic of the original Winstrol Depot presentation.
These characteristics explain why stanozolol is commonly referenced in non-medical cutting phases where a hardening, non-aromatizing compound is preferred.
Stanozolol injectable has a relatively short duration of activity compared to oil-based compounds. Because it is water-based, it requires more frequent injection than oil-based anabolic steroids to maintain stable blood levels.
Kalpa Pharmaceuticals offers several injectable and oral anabolic formulations built around different compounds. The main practical distinctions between these preparations involve the compound's aromatization rate, ester composition, and intended use context.
For oral stanozolol preparations, Stanoxyl 10 and Stanoxyl 50 provide stanozolol in tablet form. For other non-aromatizing injectables, Masteroxyl 100 provides drostanolone propionate. For multi-compound cutting blends, Cutaxyl 150 mg combines drostanolone propionate, testosterone propionate, and trenbolone acetate.
The information below is provided for educational reference only. Stanozolol is a prescription-class androgen in jurisdictions where it remains available; medical use requires appropriate diagnosis, clinical supervision and ongoing monitoring. Non-medical use falls outside approved indications.
In non-medical bodybuilding settings, stanozolol injectable is commonly referenced in the range of 50 mg every other day, or approximately 150–200 mg per week, though such use falls outside approved medical indications. Because stanozolol is water-based and has a shorter duration of activity than oil-based compounds, it requires more frequent administration.
| Use Case | Common Reference Range | Injection Frequency |
|---|---|---|
| Non-medical cutting phase | 50 mg per injection | Every other day |
| Pre-contest conditioning | 50 mg per injection | Daily or every other day |
| Stacking with a testosterone base | Typically combined with an aromatizable compound | Per cycle protocol |
In non-medical bodybuilding contexts, stanozolol is frequently referenced as a secondary compound stacked alongside a testosterone base during cutting phases. Because stanozolol does not aromatize, a testosterone base is often included to maintain physiological estrogen levels and support joint comfort. Kalpa offers several testosterone preparations that are commonly referenced in this context, including Testoxyl Propionate and Testoxyl Cypionate 250.
Stanozolol may also be referenced alongside oral compounds or other injectables such as Trenboxyl Acetate during cutting phases. Cycle structure, duration and support compounds should be considered in the context of individual experience, health status and bloodwork where possible.
Stanozolol does not aromatize, so estrogenic side effects such as gynecomastia and water retention are not a concern through the aromatization pathway. However, stanozolol is associated with joint dryness and discomfort in some users, and it is considered liver-stressful in its oral form.
Stanozolol may also adversely affect cholesterol levels, particularly HDL. Cardiovascular markers should be monitored during use. Aromatase inhibitors such as Arimixyl are typically less relevant with stanozolol alone, but may be referenced when stacking with aromatizable compounds.
After completing a cycle with Stanoxyl Depot 50 mg, post-cycle therapy is commonly recommended to help restore endogenous testosterone production and support hormonal recovery. Agents such as Clomixyl or Nolvaxyl are commonly referenced for this purpose.
PCT protocols vary based on cycle length, compounds used and individual factors. Bloodwork and, where possible, medical guidance can help inform recovery strategy.
Dosing strategies, support compounds and recovery protocols should be adjusted based on experience level and bloodwork where possible. The information above is for educational reference and does not constitute medical advice.
Stanozolol is an androgen that can affect hormonal, reproductive, cardiovascular, hepatic and hematologic function. Medical use requires appropriate diagnosis, clinical supervision and ongoing monitoring.
Stanozolol is not currently marketed as an FDA-approved human pharmaceutical product in the United States. The original Winstrol brand was approved by the FDA but has been discontinued. Its safety and efficacy have not been established through current clinical trial processes for human pharmaceutical approval.
Use of stanozolol at supraphysiologic levels for bodybuilding or performance enhancement falls outside any approved indication and can increase exposure to androgen-related adverse effects.
Higher-than-physiologic stanozolol exposure can carry additional health risks. Product concentration and laboratory verification do not establish that non-medical use is safe or appropriate for an individual.
Stanozolol can suppress endogenous testosterone production through negative feedback on the hypothalamic-pituitary-gonadal axis. This can lead to reduced testicular function and impaired fertility.
Stanozolol has been associated with hepatotoxicity, particularly in its oral C17-alpha-alkylated form. Case reports have documented severe cholestasis and acute renal failure in athletes abusing stanozolol. Bile cast nephropathy, a form of kidney injury secondary to cholestatic jaundice, has been reported in association with stanozolol use.
Stanozolol may also adversely affect cholesterol levels and is associated with joint dryness in some users. Individual response and risk vary according to health status, exposure and other factors.
Anabolic steroid use is not appropriate for everyone. Medical guidelines identify circumstances in which androgen therapy should be avoided or carefully evaluated, including known or suspected prostate or male breast cancer, elevated hematocrit, certain cardiovascular conditions, thrombophilia, liver disease and near-term fertility plans.
Existing cardiovascular disease, liver conditions, abnormal blood counts and other medical conditions should be discussed with a qualified healthcare professional before any androgen use is considered.
Medically supervised androgen therapy typically involves follow-up assessment to evaluate treatment response, adverse effects and relevant laboratory markers. Monitoring may include testosterone concentrations, hematocrit, lipid profile, and liver function tests given stanozolol's hepatic considerations.
For non-medical use of Stanoxyl Depot 50 mg, such monitoring is not typically performed, which increases the risk of unrecognized adverse effects.
Keep the vial securely stored and protected from conditions that could compromise the product or container. Inspect the vial and solution before use and do not use a product that appears damaged, contaminated or otherwise abnormal.
Keep all medications and injectable products out of the reach of children. Follow the storage instructions provided with the product packaging.
Stanoxyl Depot 50 mg is supplied through the official Kalpa Pharmaceuticals distribution chain and shipped in original manufacturer packaging with discreet, privacy-focused handling.
The outer shipping package remains discreet, with privacy-focused handling and no unnecessary external product details. Products are supplied through the official Kalpa Pharmaceuticals distribution chain.
To verify your Stanoxyl Depot 50 mg product, use the security code on the vial label and cross-check it on the Kalpa official site. Official Kalpa Pharmaceuticals presentation, batch-linked lab proof, and original packaging help reinforce product legitimacy and buyer confidence.
For complete delivery details, tracking policy, and reshipment terms, please see our Shipping Info page.
Proper storage conditions help preserve formulation stability and overall product integrity throughout shelf life.
Store at controlled room temperature (15–25°C) and protect from excessive heat, moisture, and direct light. Maintaining stable conditions helps preserve the integrity of the water-based suspension.
Keep the vial in its original packaging until use. Do not freeze. Before administration, inspect the solution and avoid use if it appears discolored, contains particulate matter, or if the vial or seal is compromised.
Keep out of reach of children. Follow proper handling and sterile injection practices when administering the product.
Answers to common questions about Stanoxyl Depot 50 mg, stanozolol, release characteristics, product strength and how it compares to other preparations.
Stanozolol is not indicated for increasing height. In pediatric contexts, anabolic steroids can accelerate bone maturation and may cause premature closure of the growth plates, which could potentially reduce final adult height rather than increase it.
Any use of stanozolol in adolescents or children is medically inappropriate outside of specific clinical supervision. Height-related concerns should be discussed with a qualified healthcare professional.
Stanozolol can suppress endogenous testosterone production and impair fertility. It has been associated with hepatotoxicity, particularly in its oral form, and case reports have documented severe cholestasis and acute renal failure in athletes abusing stanozolol.
Other potential effects include adverse changes in cholesterol levels, joint dryness, and androgenic effects in predisposed individuals. Individual response and risk vary.
Case reports have documented acute renal failure and bile cast nephropathy in association with stanozolol use, particularly when cholestatic jaundice develops. These reports describe serious kidney complications in athletes abusing stanozolol.
Kidney function should be monitored during any use of stanozolol, and any signs of jaundice or reduced kidney function should prompt immediate medical evaluation.
Stanozolol is one of the most frequently detected substances in anti-doping testing. Detection windows vary based on the testing method and individual metabolism, but stanozolol metabolites can be detected in urine for weeks to months after use.
Nail and hair testing can extend detection windows further. Anyone subject to anti-doping testing should be aware that stanozolol has a long detection profile.
Stanoxyl Depot 50 mg contains stanozolol, a non-aromatizing anabolic steroid. In non-medical bodybuilding settings it is commonly referenced during cutting phases for its hardening effects, though such use falls outside approved medical indications.
Because stanozolol injectable is water-based and has a shorter duration of activity than oil-based compounds, it is typically referenced as being administered every other day or daily. This frequency is a practical consideration for maintaining stable blood levels.
Stanozolol is a DHT-derived anabolic steroid that binds to the androgen receptor and promotes anabolism in skeletal muscle. It does not aromatize to estrogen, which is why it is commonly referenced for cutting phases where water retention is undesirable.
There is no single best compound for cutting. Stanozolol is commonly referenced during cutting phases because it does not aromatize, but it is often stacked with a testosterone base and other compounds.
Kalpa Pharmaceuticals offers several products that are commonly referenced in this context, including Cutaxyl 150 mg as a multi-compound cutting blend and Stanoxyl 10 as an oral stanozolol preparation.
Both contain stanozolol, but with different routes of administration. Stanoxyl Depot 50 mg is an injectable water-based preparation, which bypasses first-pass liver metabolism. Stanoxyl 10 and Stanoxyl 50 are oral C17-alpha-alkylated forms, which are subject to first-pass metabolism and are considered more liver-stressful.
A milligram amount cannot be classified as appropriate or excessive without considering the medical indication, individual response, laboratory results, treatment schedule and the specific product being used. In non-medical contexts, stanozolol injectable is commonly referenced at 50 mg every other day.
It is also important to distinguish a dose in milligrams from a product's concentration in mg/mL. Stanoxyl Depot 50 mg is labeled at 50 mg/mL; that concentration does not by itself specify how much should be administered.
Stanoxyl Depot 50 mg is labeled at 50 mg of stanozolol per mL. It is supplied in a 10 mL vial, giving 500 mg of total labeled stanozolol content per vial.